Isthmus Partners LLC lowered its stake in shares of Utah Medical Products, Inc. (NASDAQ:UTMD - Free Report) by 19.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 32,062 shares of the medical instruments supplier's stock after selling 7,905 shares during the period. Isthmus Partners LLC owned 0.92% of Utah Medical Products worth $2,145,000 at the end of the most recent quarter.
Other large investors also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets boosted its position in shares of Utah Medical Products by 102.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,117 shares of the medical instruments supplier's stock valued at $75,000 after acquiring an additional 566 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in Utah Medical Products by 72.1% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 10,337 shares of the medical instruments supplier's stock worth $692,000 after purchasing an additional 4,330 shares during the period. Minerva Advisors LLC boosted its holdings in Utah Medical Products by 461.8% in the 3rd quarter. Minerva Advisors LLC now owns 42,328 shares of the medical instruments supplier's stock valued at $2,818,000 after purchasing an additional 34,794 shares during the last quarter. Seizert Capital Partners LLC grew its stake in shares of Utah Medical Products by 58.3% in the 3rd quarter. Seizert Capital Partners LLC now owns 5,736 shares of the medical instruments supplier's stock valued at $384,000 after buying an additional 2,112 shares during the period. Finally, Bard Associates Inc. increased its holdings in shares of Utah Medical Products by 1.1% during the 3rd quarter. Bard Associates Inc. now owns 19,781 shares of the medical instruments supplier's stock worth $1,329,000 after buying an additional 224 shares during the last quarter. 69.60% of the stock is currently owned by hedge funds and other institutional investors.
Utah Medical Products Price Performance
Shares of NASDAQ:UTMD traded up $0.10 during midday trading on Friday, reaching $65.25. 8,745 shares of the company's stock were exchanged, compared to its average volume of 22,026. The stock has a market cap of $221.20 million, a price-to-earnings ratio of 15.28 and a beta of 0.08. Utah Medical Products, Inc. has a fifty-two week low of $63.38 and a fifty-two week high of $87.21. The firm's 50 day simple moving average is $65.69 and its two-hundred day simple moving average is $67.11.
Utah Medical Products Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, January 3rd. Shareholders of record on Monday, December 16th will be given a dividend of $0.305 per share. The ex-dividend date of this dividend is Monday, December 16th. This is a boost from Utah Medical Products's previous quarterly dividend of $0.30. This represents a $1.22 dividend on an annualized basis and a dividend yield of 1.87%. Utah Medical Products's dividend payout ratio (DPR) is currently 28.10%.
Wall Street Analysts Forecast Growth
Separately, StockNews.com cut Utah Medical Products from a "strong-buy" rating to a "buy" rating in a report on Thursday, November 7th.
Read Our Latest Research Report on UTMD
Utah Medical Products Profile
(
Free Report)
Utah Medical Products, Inc develops, manufactures, and distributes medical devices for the healthcare industry worldwide. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems.
Featured Stories
Before you consider Utah Medical Products, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Utah Medical Products wasn't on the list.
While Utah Medical Products currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
